Foundayo vs Trulicity: New Oral Against Old Weekly
Foundayo (orforglipron, Eli Lilly) vs Trulicity (dulaglutide, Eli Lilly)
Last verified May 2026
The verdict
ATTAIN-1 reported -11.1% at 72 weeks for Foundayo in obesity; Trulicity's program reported about -3 kg at 52 weeks in diabetes. ⚠ Trulicity was never trialed as a weight drug and is not labeled as one, so this is a comparison readers make rather than one the evidence invites. ★ What Trulicity genuinely holds is the finished cardiovascular trial — REWIND cut major cardiac events 12% — plus dedicated kidney evidence. Foundayo has neither yet.
Side-by-side comparison
| Field | Foundayo | Trulicity |
|---|---|---|
| How you take it | A tablet, once a day | An injection under the skin, once a week |
| How it works | A small-molecule GLP-1 receptor agonist — not a peptide, so the gut does not destroy it | A peptide GLP-1 receptor agonist fused to an antibody fragment, which is what makes it last a week |
| The dose ladder | 0.8, 2.5, 5.5, 9, 14.5, then 17.2 mg daily | 0.75, 1.5, 3.0, then 4.5 mg weekly |
| Weight lost at the top dose | -11.1% over 72 weeks at 17.2 mg (ATTAIN-1) | About -3 kg over 52 weeks at 1.5 mg (AWARD program) |
| Blood-sugar reduction in diabetes | -1.3% to -1.6% over 40 weeks at 17.2 mg (ACHIEVE-1) | -1.1% over 26 to 40 weeks at 1.5 mg |
| What it is approved to treat | Long-term weight management, from 1 April 2026. The diabetes filing is still pending | Type 2 diabetes, plus reducing cardiac risk in diabetes with heart disease or risk factors |
| Whether a trial proved it prevents heart attacks and strokes | None reported. One is planned | REWIND: major cardiac events down 12% across 9,901 participants |
| Youngest approved age | Adults only, 18 and over | 10 and over, for type 2 diabetes |
| Evidence in advanced kidney disease | Little. Significant kidney impairment was excluded from the pivotal trial | AWARD-7 matched insulin on blood sugar in stage 3-4 kidney disease, with less decline in kidney function |
What each one costs in the compounded market
Standing monthly cash prices from the 556 sellers on this register. These are compounded preparations, not the approved products compared above.
Foundayo — orforglipron
from $149 /mo
2 sellers publish a standing price; the median is $149 a month.
Trulicity — dulaglutide
No seller on this register publishes a compounded price for it. For a drug still in trials that is expected — and anyone selling it anyway is doing so outside the system this register covers.
⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.
Frequently asked questions
Are Foundayo and Trulicity the same drug?
No. Foundayo is orforglipron and Trulicity is dulaglutide — different molecules. Results with one do not predict results with the other.
What does a compounded version of each actually cost?
Across the 556 sellers in this register, the cheapest standing monthly cash prices we hold are orforglipron from $149 a month. ⛔ A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.
Can I switch from Foundayo to Trulicity?
Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.
Which one should I ask for?
That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.
References
- 1.Wharton S, Aronne LJ, Garvey WT, et al. Orforglipron, a Once-Daily Oral Nonpeptide GLP-1 Receptor Agonist, for the Treatment of Obesity (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.
- 2.Rosenstock J, Frias JP, Fernández Landó L, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Adults with Type 2 Diabetes (ACHIEVE-1). N Engl J Med. 2025. PMID: 40544435.
- 3.Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. PMID: 31189511.
- 4.Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018. PMID: 29910024.
- 5.Eli Lilly and Company. Foundayo (orforglipron) tablets — FDA prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
- 6.Eli Lilly and Company. Trulicity (dulaglutide) injection — FDA prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
Related comparisons
- Wegovy vs Zepbound
- Ozempic vs Mounjaro
- Semaglutide vs Tirzepatide
- Rybelsus vs Ozempic
- Mounjaro vs Zepbound
- Foundayo vs Rybelsus
See the full drug-vs-drug verdict index or provider rankings.